Lifestyle

Psychedelic Retreats Market Set to Cross $1 Trillion By 2027

Jun 14 • 6 min read

The market for psychedelic retreats is on a remarkable trajectory, with projections indicating it will surpass the $1 trillion mark by 2027. This anticipated milestone reflects the rapid expansion and increasing acceptance of psychedelic therapy as an effective treatment for various mental health conditions. The combination of scientific research, regulatory advancements, and shifting societal attitudes…

UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on Perception

Jun 14 • 6 min read

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans. This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use….

Lykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSD

Jun 14 • 5 min read

A week after an FDA committee voted against recommending midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is working to clarify the situation and address concerns that have emerged in the broader conversation. This effort comes in the wake of significant public discourse surrounding the potential benefits and risks associated with the psychoactive…

Effective Psychedelic Treatment for Long-COVID Symptoms: A Case Study

Jun 7 • 4 min read

Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist even after an individual has seemingly recovered from COVID-19. These symptoms can include cognitive impairment, fatigue, depression, anxiety, headaches, and joint pain. Currently, effective treatments for long-COVID are limited. However, a recent case study has highlighted the potential of…

Proposal to Approve MDMA for PTSD Treatment Fails

Jun 5 • 7 min read

A federal panel of independent health advisers convened yesterday to deliberate on a groundbreaking proposal to approve MDMA as a treatment for post-traumatic stress disorder (PTSD). Ultimately, Lykos’ proposal to approve MDMA for PTSD treatment was rejected with a decisive 1-10 vote, casting doubt on the possibility of federal approval later this summer. Examining the…

Pages: 123456789101112131415161718192021